Therefore, we hypothesized that the difference in immunophenotype between BRCA1- and BRCA2-deficient breast cancers may be attributed to PTEN loss, such as that mediated by inactivating PTEN gene mutations. Here, BRCA2 is linked to breast carcinoma.